(Total Views: 350)
Posted On: 04/30/2020 10:04:34 PM
Post# of 716
Brilacidin
Innovation Pharmaceuticals Inc.
Under terms of a material transfer agreement with a public health-focused U.S. university and top coronavirus expert, virologists plan to evaluate the potential antiviral properties of brilacidin, Innovation's defensin-mimetic drug candidate, as a potential COVID-19 vaccine; the research is independent of testing of brilacidin as a small-molecule drug against SARS-CoV-2; vero cells, a monkey kidney cell line, were pretreated with brilacidin for two hours prior to the infection, and cells treated with the vehicle alone (dimethyl sulfoxide) were maintained as controls; at 16 hours post-infection, researchers observed a dose-dependent reduction in the SARS-CoV-2 infectious viral titers from the brilacidin-treated cells as compared to the vehicle-alone control; as of April 27, results from initial testing showed brilacidin had antiviral activity in Vero cells; continued test will begin May 4
https://www.bioworld.com/COVID19products#vac
Innovation Pharmaceuticals Inc.
Under terms of a material transfer agreement with a public health-focused U.S. university and top coronavirus expert, virologists plan to evaluate the potential antiviral properties of brilacidin, Innovation's defensin-mimetic drug candidate, as a potential COVID-19 vaccine; the research is independent of testing of brilacidin as a small-molecule drug against SARS-CoV-2; vero cells, a monkey kidney cell line, were pretreated with brilacidin for two hours prior to the infection, and cells treated with the vehicle alone (dimethyl sulfoxide) were maintained as controls; at 16 hours post-infection, researchers observed a dose-dependent reduction in the SARS-CoV-2 infectious viral titers from the brilacidin-treated cells as compared to the vehicle-alone control; as of April 27, results from initial testing showed brilacidin had antiviral activity in Vero cells; continued test will begin May 4
https://www.bioworld.com/COVID19products#vac
(2)
(0)
